Agrotis A, Little P J, Saltis J, Bobik A
Baker Medical Research Institute, Alfred Baker Medical Unit, Alfred Hospital, Prahran, Victoria, Australia.
Eur J Pharmacol. 1993 Feb 15;244(3):269-75. doi: 10.1016/0922-4106(93)90152-y.
We examined the mechanisms by which Ca2+ channel antagonists inhibit the growth of smooth muscle cells by determining their effect on epidermal growth factor (EGF)-stimulated (i) induction of the early signalling gene, c-fos, (ii) incorporation of [3H]thymidine into cells as a measure of DNA synthesis, and (iii) increase in cell number. Verapamil, diltiazem, and the dihydropyridines felodipine, MDL 72892 A-15 (MDL) and nisoldipine had no effect on EGF-stimulated c-fos mRNA induction. Furthermore, only small inhibitory effects were observed on EGF-stimulated increases in cell number; felodipine, MDL, and nisoldipine at 0.3 microM inhibited EGF-stimulated cell proliferation by 9, 11, and 15%, respectively. In contrast, the dihydropyridine Ca2+ channel antagonists were found to be potent inhibitors of [3H]thymidine incorporation suggesting that they inhibit DNA synthesis. However, further examination revealed that the potent effects of dihydropyridine Ca2+ channel antagonists on [3H]thymidine incorporation were due not to an effect on incorporation of [3H]thymidine into DNA, but to a marked inhibitory effect on the cellular uptake of [3H]thymidine. Thus, we conclude that the small antiproliferative effects of the dihydropyridine antagonists are predominantly due to their ability to inhibit the activity of the salvage pathway for thymidylate synthesis in human vascular smooth muscle cells.
我们通过确定钙通道拮抗剂对表皮生长因子(EGF)刺激的以下方面的影响,来研究其抑制平滑肌细胞生长的机制:(i)早期信号基因c-fos的诱导,(ii)[3H]胸苷掺入细胞作为DNA合成的指标,以及(iii)细胞数量的增加。维拉帕米、地尔硫䓬以及二氢吡啶类药物非洛地平、MDL 72892 A-15(MDL)和尼索地平对EGF刺激的c-fos mRNA诱导没有影响。此外,仅观察到对EGF刺激的细胞数量增加有较小的抑制作用;0.3微摩尔的非洛地平、MDL和尼索地平分别抑制EGF刺激的细胞增殖9%、11%和15%。相比之下,发现二氢吡啶类钙通道拮抗剂是[3H]胸苷掺入的有效抑制剂,表明它们抑制DNA合成。然而,进一步研究表明,二氢吡啶类钙通道拮抗剂对[3H]胸苷掺入的强效作用并非由于对[3H]胸苷掺入DNA的影响,而是对[3H]胸苷细胞摄取有显著抑制作用。因此,我们得出结论,二氢吡啶类拮抗剂的小抗增殖作用主要归因于它们抑制人血管平滑肌细胞胸苷酸合成补救途径活性的能力。